**IJCRT.ORG** 

ISSN: 2320-2882



## INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# CASE STUDY ON RHEUMATIC HEART DISEASE WITH SEVERE MITRAL REGURGITATION

<sup>1</sup> Naveena B, <sup>2</sup> Vimalesh M

<sup>1, 2</sup> Students,

<sup>1</sup> Department of Pharmacy Practice,

<sup>1</sup> Arulmigu Kalasalingam College of Pharmacy, Krishnan koil, Virudunagar Dt., Tamil Nadu

#### Abstract

Rheumatic heart disease is one of the most common disease in children as it results in the group-A streptococcal infection. We present a case of a A 17 years old male patient admitted in the general medicine department with the complaints of difficulty in breathing-2 months insidious onset that was progressing NYHA-2, orthopnea that is present occasionally and palpitations for 2 month, cold and cough for 15 days on and off associated with sputum production with throat pain and chest pain. The patient had a past medical history of recurrent cold and cough – recurrent re-episodes of infection for past 1 year. The ECHO cardiogram of this patient demonstrated that the patient having ejection fraction of 60%, and left atrium is dilated and both the leaflets of mitral valve are thickened. There is RHD with severe mitral regurgitation. His symptoms revealed the diagnosis of rheumatic heart disease with severe mitral regurgitation. The patient was treated with phenoxy methyl penicillin. He was advised to go to another institution within 2 days for valve replacement surgery.

#### INTRODUCTION

Rheumatic heart disease is the most common cardiovascular disease among children and young adults worldwide. More than 40million people were living with RHD and about 3,00,000 individuals died from RHD in the year 2017 [1]. It is related to post-infectious autoimmune mechanisms driven to group-A streptococcus (GAS) antigens. Jones criteria are the main diagnosis guidelines, by combining major and minor signs at presentation [2]. RHD causes inflammation of the cardiac valves, initially leading to clinically silent valvular disease and ultimately severe permanent damage. Individuals with RHD are at increased risk of complications such as CHF, arrhythmias including atrial fibrillation, stroke, infective endocarditis, poor maternal and fetal outcomes, and premature death [3, 4]. Echocardiography is the most cost-effective tool for population screening and estimating the prevalence of RHD [5]. There is no clear outcome predictor and the adherence to long-term penicillin prophylaxis is still challenging for these patient's care. Penicllin is prescribed for the initial attack and

for prophylaxis of new attacks and close follow-up surveillance is currently recommended by expert consensus. Long-acting benzathine penicillin is the recommended treatment, with the first dose prescribed at diagnosis, followed by 3-week interval age-appropriated dosing, according to WHO experts guidelines [6-8].

This study aimed to examine the presentation profile, over-lap of clinical features and outcomes in a case series from a specialised clinic. Knowledge of common presentations of this once ubiquitous disease thus remains clinically useful.

#### **CASE PRESENTATION**

A 17 years old male patient admitted in the general medicine department with the complaints of difficulty in breathing-2 months insidious onset that was progressing NYHA-2, orthopnea that is present occasionally and palpitations for 2 month, cold and cough for 15 days on and off associated with sputum production with throat pain and chest pain. The patient had a past medical history of recurrent cold and cough – recurrent re-episodes of infection for past 1 year.

The patient was afebrile, and on invitigations on the vital signs showed abnormal pulse rate i.e. 150beats\min. Lung auscultation revealed bilateral diffused crepts. Cardiovascular examination demonstrated on **inspection** apical impulses seen in 6<sup>th</sup> and 7<sup>th</sup> intercoastal space (ICS) in midclavicular line and presentation of intercoastal refractions, on **palpation** apical impulses confirmed to be 6<sup>th</sup> and 7<sup>th</sup> ICS in midclavicular line, and shows hyperdynamic apical impulse, and the presentation of thrill and palpable P<sub>2</sub> and on **auscultation** pansystolic murmur present in the mitral area that was radiating to the axilla and pulmonary area demonstrated that loud P<sub>2</sub>.

Laboratory data was significant for Anti-streptolysin O (ASO) of 125mg/dl and C-reactive protein (CRP) of 5.6%. The patient had microcytic hypochromic anemia with haemoglobin (Hb) of 8.1g/dl. The patient had elevated WBC i.e. 15,700 WBCs/microliter this shows patient had infection. The patient had the potassium levels of 3.1mEq/l this low level of potassium causes palpitation. ECG of this patient showed that sinus tachycardia, Larged P-wave terminal force in V<sub>1</sub>, right atrial enlargement and slight ST elevation and T wave abnormality.

The ECHO cardiogram of this patient demonstrated that the patient having ejection fraction of 60%, and left atrium is dilated and both the leaflets of mitral valve are thickened. There is RHD with severe mitral regurgitation.

The patient had long arms, fingers and feets, that shows this patient having marfonoid syndrome.

#### **DISCUSSION**

Rheumatic fever is a delayed consequences of pharyngeal infection with GAS. The GAS cell wall contains M proteins that are antigenically similar to proteins found in the human body. When an immune response is mounted to the initial GAS infection, anti-bodies are formed against the protein, which then circulate throughout the body and bind to normal protein epitopes found in human tissue. The complexes formed then induce a T-cell mediated attack on normal tissues, causing long-term sequelae of the disease.

From all the above findings the patient was assessed to have **RHD with severe MR/Marfonoid habitus/Microcytic Hypochromic anemia/ B\L bronchiectasis** and evaluation of infective endocarditis.

### RESULTS

The patient was treated with phenoxy methyl penicillin, it is a pencillin derivative, penicillin which is a firstline choice for RHD. The patient's heart rate was controlled with verapamil and metoprolol. His anemia was treated with iron sucrose and infection was controlled with antibiotics. The patient had bronchiectasis which was controlled with foracort (formoterol+budesonide) inhaler. He was advised to go to another institution within 2 days for valve replacement surgery.

After starting iron sucrose therapy the patient's Hb level was increased upto 1g/dl on the first day of treatment.

#### **REFERENCES**

- [1]. Okello E, Ndagire E, Atala J, Bowen AC, DiFazio MP, Harik NS, Longenecker CT, Lwabi P, Murali M, Norton SA, Omara IO. Active case finding for rheumatic fever in an endemic country. Journal of the American Heart Association. 2020 Aug 4;9(15):e016053.
- [2]. Carvalho SM, Dalben I, Corrente JE, Magalhães CS. Rheumatic fever presentation and outcome: a case-series report. Revista brasileira de reumatologia. 2012;52:241-6.
- [3]. Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Scientific reports. 2019 Nov 19;9(1):1-4.
- [4]. Zühlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido-Katya Mauff B, Islam S, Daniels R, Francis V, Ogendo S, Gitura B. Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low-and middle-income countries: two-year follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY Study). Circulation. 2016 Nov 8;134(19):1456-66.
- [5]. Zühlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. Global heart. 2013 Sep 1;8(3):189-95.
- [6]. Nordet P. WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from phase I (1986-90). Bulletin of the World Health Organization. 1992 Mar 1;70(2):213-9.
- [7]. World Health Organization. Rheumatic Fever and Rheumatic Heart Disease: Report of a WHO expert Consultation, Geneva, 29 October-1 November, 2001. World Health Organization; 2004 Feb 4. [8].Barbosa PJ, Mülle RE, Andrade JP, Braga AL, Achutti AC, Ramos AI. Diretrizes Brasileiras para

diagnóstico, tratamento e prevenção da febre reumática. Arq Bras Cardiol. 2009;93(Suppl 4):127-47.